• UCF Research & Commercialization
  • Sponsored Programs
  • Tech Transfer
  • Technology Incubator
  • Compliance
  • Research Foundation
  • Centers
  •     |     Search
     
    Print  
    Available Technologies / Life Sciences / LifeScienceTech - #7599
     
    Methods of Inducing and Preventing Neurofibromatosis in Schwann Cells
     PDF Version  

     

    Background
    The neurofibromatoses are genetic disorders of the nervous system that primarily affect the development and growth of neural cell tissues.  These disorders cause tumors to grow on nerves and produce other abnormalities such as skin changes and bone deformities.  Although many affected persons inherit the disorder, between 30 and 50 percent of new cases arise spontaneously through mutation.  These disorders have been classified into two types:  neurofibromatosis type 1 (NF1) and neurofibromatosis type 2 (NF2).  Neurofibromatosis type 2 is caused by a mutation on chromosome 22q12 in the nf2 gene that lead to loss of expression of schwannomin (Sch), also called merlin, which is a tumor suppressor.  Symptoms include, acoustic neuromas on the vestibulocochlear nerve leading to hearing loss.  Patients with NF2 may also develop other brain tumors, as well as spinal tumors. The current invention describes a model system for identifying new therapies for NF2.  This invention also describes a method for preventing inactivation of the Schwannomin’s tumor suppressor activity in Schwann cells.  

    Invention
    The invention provides a method for inducing neurofibromatosis type 2 (NF2) in Schwann cells for testing of new treatment drugs, as well as a method for preventing the inactivity of tumor suppressors via a blocking agent, tyrphostin AG825.
     
    Application
    The invention can provide a model for neurofibromatosis (NF2) which would allow for testing of new therapeutic agents.

    Advantages
    •    Provides reliable laboratory methods to induce NF2 modeling.
    •    The blocking agent is a possible agent for further pharmaceutical options.

    Lead Inventor
    Cristina Fernandez-Valle, Ph.D.

    Selected References
    Thaxton C, Lopera J, Bott M, Baldwin ME, Kalidas P, Fernandez-Valle C. Phosphorylation of the NF2 tumor suppressor in Schwann cells is mediated by Cdc42-Pak and requires paxillin binding. 2007 Feb;34(2):231-42.

    Contact
    Attn: Svetlana Shtrom, Ph.D., MBA
    University of Central Florida
    Office of Research and Commercialization
    12201 Research Parkway, Suite 501
    Orlando, Fl 32826-3246
    Phone: 407.823.5150
    Fax: 407.823.3299
    sshtrom@mail.ucf.edu


    UCF ID # 7599

     
     
    Print  
     
    Print  
  • Home
  • Contact Us
  • Site Credit
  • © 2008 UCF Office of Research & Commercialization All Rights Reserved
    UCF Office of Research & Commercialization | 12201 Research Parkway, Suite 501 | Orlando, FL 32826
    Phone: 407.823.3778 | Fax: 407.823.3299